On June 8, 2026, MetaVia, Inc. (MTVA) announced the presentation of new late-breaking data for DA-1726, the company's oxyntomodulin analog targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), and vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist. The data were presented in late-breaking poster sessions at the American Diabetes Association's (ADA) 2026 Scientific Sessions. New PK data for DA-1726 showed a dose-proportional profile that supports once-weekly dosing. For vanoglipel, preclinical data showed that combination treatment with resmetirom resulted in synergistic weight-loss effects while when combined with metformin there was enhanced glycemic control and body weight reductions. We continue to anticipate topline results from Part 3 of the Phase 1 trial of DA-1726 in the fourth quarter of 2026.
